Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Sep;52(9):3175-9.
doi: 10.1128/JCM.01094-14. Epub 2014 Jun 20.

Practical agar-based disk potentiation test for detection of fosfomycin-nonsusceptible Escherichia coli clinical isolates producing glutathione S-transferases

Affiliations

Practical agar-based disk potentiation test for detection of fosfomycin-nonsusceptible Escherichia coli clinical isolates producing glutathione S-transferases

Genki Nakamura et al. J Clin Microbiol. 2014 Sep.

Abstract

The number of reports concerning Escherichia coli clinical isolates that produce glutathione S-transferases responsible for fosfomycin resistance (FR-GSTs) has been increasing. We have developed a disk-based potentiation test in which FR-GST producers expand the growth inhibition zone around a Kirby-Bauer disk containing fosfomycin in combination with sodium phosphonoformate (PPF). PPF, an analog of fosfomycin, is a transition-state inhibitor of FosA(PA), a type of FR-GST from Pseudomonas aeruginosa. Considering its mechanism of action, PPF was expected to inhibit a variety of FR-GSTs. In the presence of PPF, zone enlargement around the disk containing fosfomycin was observed for FosA3-, FosA4-, and FosC2-producing E. coli clinical isolates. Moreover, the growth inhibition zone was remarkably enlarged when the Mueller-Hinton (MH) agar plate contained 25 μg/ml glucose-6-phosphate (G6P). When we retrospectively tested 12 fosfomycin-resistant (MIC, ≥256 μg/ml) E. coli clinical isolates from our hospital with the potentiation test, 6 FR-GST producers were positive phenotypically by potentiation disk and were positive for FR-GST genes: 5 harbored fosA3 and 1 harbored fosA4. To identify the production of FR-GSTs, we set the provisional cutoff value, 5-mm enlargement, by adding PPF to a fosfomycin disk on the MH agar plates containing G6P. Our disk-based potentiation test reliably identifies FR-GST producers and can be performed easily; therefore, it will be advantageous in epidemiological surveys and infection control of fosfomycin-resistant bacteria in clinical settings.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Predicted amino acid sequence of fosfomycin resistance determinants. *, amino acid residues conserved among the eight fosfomycin resistance determinants; colons and dots, amino acid substitutions that result in homologous amino acid residues. The resistance determinants (GenBank accession no.) are FosAPA (AAT49669), FosATN (AAA98399), FosA2 (ACC85616), FosA3 (BAJ10054), FosA4 (AB908992), open reading frame 1 (ORF1) (AAP50248), FosC (AAZ14834), and FosC2 (BAJ10053). The box indicates the conserved Thr9 residue in the fosfomycin resistance glutathione S-transferases.
FIG 2
FIG 2
(A) Potentiation by PPF in growth inhibition zone diameters around a fosfomycin disk. PPF was added to a fosfomycin disk (right side in each panel). Shown are a fosA3-positive strain on an MH plate (upper left) and MH-G6P plate (upper right), and an FR-GST-negative strain on an MH plate (lower left) and MH-G6P plate (lower right). (B) The results of fosC2-positive (left) and fosA4-positive strains on MH-G6P plates (right). FR-GST, fosfomycin resistance-mediating glutathione S-transferase; PPF, phosphonoformate; MH, Mueller-Hinton; G6P, glucose-6-phosphate.
FIG 3
FIG 3
Summary of changes in growth inhibition zone diameter with PPF. The y axis represents the enlargement of the growth inhibition zone (mm) by PPF. FR-GST, fosfomycin resistance-mediating glutathione S-transferase; PPF, phosphonoformate; MH, Mueller-Hinton; G6P, glucose-6-phosphate.

Similar articles

Cited by

References

    1. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, Chaudhary U, Doumith M, Giske CG, Irfan S, Krishnan P, Kumar AV, Maharjan S, Mushtaq S, Noorie T, Paterson DL, Pearson A, Perry C, Pike R, Rao B, Ray U, Sarma JB, Sharma M, Sheridan E, Thirunarayan MA, Turton J, Upadhyay S, Warner M, Welfare W, Livermore DM, Woodford N. 2010. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect. Dis. 10:597–602. 10.1016/S1473-3099(10)70143-2. - DOI - PMC - PubMed
    1. Bergen PJ, Landersdorfer CB, Lee HJ, Li J, Nation RL. 2012. ‘Old’ antibiotics for emerging multidrug-resistant bacteria. Curr. Opin. Infect. Dis. 25:626–633. 10.1097/QCO.0b013e328358afe5. - DOI - PMC - PubMed
    1. Moffatt JH, Harper M, Harrison P, Hale JD, Vinogradov E, Seemann T, Henry R, Crane B, St Michael F, Cox AD, Adler B, Nation RL, Li J, Boyce JD. 2010. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob. Agents Chemother. 54:4971–4977. 10.1128/AAC.00834-10. - DOI - PMC - PubMed
    1. Takahata S, Ida T, Hiraishi T, Sakakibara S, Maebashi K, Terada S, Muratani T, Matsumoto T, Nakahama C, Tomono K. 2010. Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli. Int. J. Antimicrob. Agents 35:333–337. 10.1016/j.ijantimicag.2009.11.011. - DOI - PubMed
    1. Wachino J, Yamane K, Suzuki S, Kimura K, Arakawa Y. 2010. Prevalence of fosfomycin resistance among CTX-M-producing Escherichia coli clinical isolates in Japan and identification of novel plasmid-mediated fosfomycin-modifying enzymes. Antimicrob. Agents Chemother. 54:3061–3064. 10.1128/AAC.01834-09. - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data